# OnCo record mb-105 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/mb-105/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "mb-105" ;
  schema:name "MB-105"@en ;
  schema:alternateName "CD5.CAR/28zeta CAR T cells (Baylor phase 1, name used in NCT03081910)"@en ;
  schema:description "MB-105 is an experimental autologous CAR T-cell therapy from March Biosciences, in phase 2 trials for CD5-positive T-cell lymphoma and T-cell acute lymphoblastic leukaemia."@en ;
  schema:url <https://onco.cc/drugs/mb-105/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://march.bio/mb-105/>, <https://march.bio/mb-105/>, <https://march.bio/pipeline/>, <https://clinicaltrials.gov/api/v2/studies/NCT06534060>, <https://clinicaltrials.gov/search?intr=MB-105> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Autologous CAR T-cell therapy" ;
  onco:cancers <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:companies <https://onco.cc/companies/march-biosciences/> ;
  onco:trials <https://onco.cc/trials/nct06534060/>, <https://onco.cc/trials/nct07340814/> .